Lung Cancer/Thoracic Malignancies
Patient Safety and Quality
AMA PRA Category 1 Credits 1.00
CAMPEP Credits: 1.00
MDCB Credits: 1.00
Timur Mitin, MD, PhD
Oregon Health and Science University
Portland, Oregon
Patients with interstitial lung disease (ILD), especially those with pulmonary fibrosis, are at increased risk of developing lung cancer. Management of lung cancer in patients with ILD is particularly challenging. Diagnosis can be complicated by difficulty differentiating lung nodules from areas of focal fibrosis, and percutaneous biopsy approaches confer an increased risk of complications in those with pulmonary fibrosis. Lung cancer treatment in these patients pose several specific considerations. The degree of lung function impairment may preclude surgical resection of any type. Surgical resection can trigger an acute exacerbation of the underlying ILD. The presence of ILD confers an increased risk of pneumonitis with radiotherapy, as well as systemic therapies. The goal of this session is to educate practicing radiation oncologists how to recognize and categorize ILD, seek multi-disciplinary input into evaluation and management of patients with ILD, include routine use of ILD-GAP score into clinical practice in order to balance the risk of lung cancer progression vs. death from ILD, and manage pneumonitis and acute exacerbations of the underlying ILD after radiation therapy.
Speaker: Timur Mitin, MD, PhD – Oregon Health and Science University
Speaker: Cheilonda Johnson, MD – University of Pennsylvania
Speaker: Mizuki Nishino, MD – Dana-Farber/Brigham and Women's Cancer Center
Speaker: Christopher Goodman, MD – University of Western Ontario
Speaker: Timur Mitin, MD, PhD – Oregon Health and Science University